Jan 18, 2013, 08.15 AM | Source: Moneycontrol.com
On January 17, 2013 Ramjidas & Sons sold 350,000 shares of Ajanta Pharma at Rs 399.44 on the NSE and sold 150,000 shares at Rs 397.50 on the BSE.
However, RBA Finance And Invest Co bought 150,000 shares at Rs 397.50 on the BSE and bought 350,000 shares at Rs 399.44 on the NSE.
In the previous trading session, the share closed at Rs 406.75, up Rs 14.60, or 3.72%. It has touched an intraday high of Rs 409 and an intraday low of Rs 390.
The company's trailing 12-month (TTM) EPS was at Rs 62.81 per share. (Sep, 2012). The stock's price-to-earnings (P/E) ratio was 6.48. The latest book value of the company is Rs 116.05 per share. At current value, the price-to-book value of the company was 3.5. The dividend yield of the company was 0.92%.
The share touched its 52-week high Rs 505 and 52-week low Rs 162.35 on 21 September, 2012 and 18 January, 2012, respectively. Currently, it is trading 19.46% below its 52-week high and 150.54% above its 52-week low. Market capitalisation stands at Rs 952.49 crore.
Buy Ajanta Pharma; target of Rs 1780: ICICIDirect
ICICIDirect is bullish on Ajanta Pharma and has re
Buy Ajanta Pharma, Havells India, Tata Elxsi:Â Ashish Kyal
Ashish Kyal of wavesstrategy.com recommends buying
Buy Ajanta Pharma on dips, sell PSU banks: Sudarshan Sukhani
Sudarshan Sukhani of s2analytics.com is of the vie
Ajanta Pharma Q3 net up 20% at Rs 111.3 crore
The company had posted a net profit of Rs 93.06 cr
Like Ajanta Pharma, HUL may test Rs 815-820: Prakash Gaba
Prakash Gaba of prakashgaba.com likes Ajanta Pharm
Here are Manoj Murlidharanâs top F&O picks
In an interview to CNBC-TV18's Latha Venkatesh and
Look at Cadila Healthcare, Dishman Pharma: Jai Bala
Jai Bala of Cashthechaos.com is of the view that o
BFSI, retail, pharma to be impacted most by Ind AS: Survey